Key Insights

Highlights

Success Rate

83% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

12.5%

3 terminated out of 24 trials

Success Rate

83.3%

-3.2% vs benchmark

Late-Stage Pipeline

25%

6 trials in Phase 3/4

Results Transparency

53%

8 of 15 completed with results

Key Signals

8 with results83% success

Data Visualizations

Phase Distribution

21Total
Not Applicable (9)
P 1 (2)
P 2 (4)
P 3 (5)
P 4 (1)

Trial Status

Completed15
Unknown3
Terminated3
Withdrawn2
Active Not Recruiting1

Trial Success Rate

83.3%

Benchmark: 86.5%

Based on 15 completed trials

Clinical Trials (24)

Showing 20 of 20 trials
NCT05545839Not ApplicableCompleted

Transition to Adulthood Through Coaching and Empowerment in Rheumatology

NCT05715463Not ApplicableActive Not Recruiting

Rheumatology-based Adaptive Intervention for Social Determinants and Health Equity

NCT00289107Not ApplicableCompleted

Randomized Fixed Bearing vs Mobile Bearing Cruciate Substituting TKA

NCT00090571CompletedPrimary

Juvenile Rheumatoid Arthritis Research Registry

NCT00289094Not ApplicableCompleted

Randomized Fixed Bearing vs Mobile Bearing Cruciate Retaining TKA

NCT05504382Not ApplicableUnknownPrimary

Effect of Electroacupuncture on Refractory Pain in Juvenile Rheumatoid Arthritis: Randomized Controlled Trial

NCT05114343Not ApplicableUnknown

Effectiveness and Feasibility of a Home-based Exercise Program for Adolescents With Juvenile Idiopathic Arthritis

NCT02418273Phase 1Withdrawn

Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders

NCT00078806Phase 3TerminatedPrimary

Safety and Efficacy Study of Etanercept (Enbrel®) In Children With Systemic Onset Juvenile Rheumatoid Arthritis

NCT03781375Phase 3TerminatedPrimary

Etanercept Plus Methotrexate Versus Methotrexate Alone in Children With Polyarticular Course Juvenile Rheumatoid Arthritis

NCT03780959Phase 2CompletedPrimary

Safety and Efficacy of Etanercept (Recombinant Human Tumor Necrosis Factor Receptor Fusion Protein [TNFR:Fc]) in Children With Juvenile Rheumatoid Arthritis (JRA)

NCT00286689Not ApplicableWithdrawn

Effects of Growth Hormone in Chronically Ill Children

NCT01044823Completed

Use of Thermal and 3D Imaging to Quantify Arthritis

NCT00095173Phase 3CompletedPrimary

BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis

NCT00570934Phase 3CompletedPrimary

Supplementation With Vitamin D, Calcium or Both on Calcium Absorption and Bone Mineral Content in Children With JRA

NCT00004420Not ApplicableCompletedPrimary

Study of Gammalinolenic Acid for Juvenile Rheumatoid Arthritis

NCT00010335Phase 1Completed

Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refractory Autoimmune Disorders

NCT00000429Phase 2CompletedPrimary

Calcium Supplements for Bone Health in Juvenile Rheumatoid Arthritis

NCT00443430Phase 4Completed

Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis

NCT00078793CompletedPrimary

Registry of Etanercept (Enbrel®) In Children With Juvenile Rheumatoid Arthritis

Scroll to load more

Research Network

Activity Timeline